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Summary
Complement receptor 3 (CR3, CD11b/CD18) is a multi-functional receptor
expressed predominantly on myeloid and natural killer (NK) cells. The R77H
variant of CD11b, encoded by the ITGAM rs1143679 polymorphism, is
associated robustly with development of the autoimmune disease systemic
lupus erythematosus (SLE) and impairs CR3 function, including its regulatory
role on monocyte immune signalling. The role of CR3 in NK cell function is
unknown. Leukadherin-1 is a specific small-molecule CR3 agonist that has
shown therapeutic promise in animal models of vascular injury and
inflammation. We show that Leukadherin-1 pretreatment reduces secretion of
interferon (IFN)-g, tumour necrosis factor (TNF) and macrophage
inflammatory protein (MIP)-1b by monokine-stimulated NK cells. It was
associated with a reduction in phosphorylated signal transducer and activator
of transcription (pSTAT)-5 following interleukin (IL)-121 IL-15 stimulation
(P < 002) and increased IL-10 secretion following IL-121 IL-18 stimulation
(P < 0001). Leukadherin-1 pretreatment also reduces secretion of IL-1b, IL-6
and TNF by Toll-like receptor (TLR)-2 and TLR-7/8-stimulated monocytes
(P < 001 for all). The R77H variant did not affect NK cell response to
Leukadherin-1 using ex-vivo cells from homozygous donors; nor did the
variant influence CR3 expression by these cell types, in contrast to a recent
report. These data extend our understanding of CR3 biology by demonstrating
that activation potently modifies innate immune inflammatory signalling,
including a previously undocumented role in NK cell function. We discuss the
potential relevance of this to the pathogenesis of SLE. Leukadherin-1 appears to
mediate its anti-inflammatory effect irrespective of the SLE-risk genotype of
CR3, providing further evidence to support its evaluation of Leukadherin-1 as a
potential therapeutic for autoimmune disease.
Keywords: complement receptor 3, innate immunity, Leukadherin-1, NK
cells, systemic lupus erythematosus
Introduction
Complement receptor 3 (CR3), also known as Mac1 or
the aMb2 integrin (CD11b/CD18), is a multi-functional
receptor expressed constitutively on neutrophils, myeloid
cells and natural killer (NK) cells, as well as on subsets
of activated lymphocytes. It binds a diverse range of
ligands, which include iC3b (the stable, biologically
active, solid-phase degradation fragment of complement
component C3), the intercellular adhesion molecule
ICAM-1 and the coagulation protein fibrinogen [1,2].
CR3 has long been recognized as a mediator of cell adhe-
sion and phagocytosis, capable of triggering phagocytosis
itself and also mediating phagocytosis following ligand
engagement by glycophosphatidylinositol (GPI)-linked
FcgRIIIB (CD16b) on neutrophils [3]. Recent studies
demonstrate that CR3 also plays an important role in a
broad range of immune signalling pathways. In particu-
lar, CR3 ligation suppresses inflammatory cytokine
release following monocyte Toll-like receptor (TLR) or
interferon (IFN)-a receptor activation, positively regu-
lates TLR-4 signalling in dendritic cells and regulates B
cell receptor signalling [4–7].
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Two recent advances have increased our interest in the biol-
ogy of CR3 signalling. First, a non-synonymous (R77H) vari-
ant of the CR3 a-chain, CD11b (encoded by the common
rs1143679 variant of ITGAM), has been identified as a strong
genetic risk factor for the development of the autoimmune
disease systemic lupus erythematosus (SLE) across multiple
populations [odds ratio (OR)meta5 1.76] [8–10]. This variant
impairs CR3 function in neutrophils, monocytes and dendri-
tic cells, but a detailed understanding of all the implications of
genetically determined CR3 under-functioning will be needed
before we can begin to understand clearly the molecular path-
ways by which this disease susceptibility effect operates
[11–14]. Secondly, a specific small-molecule agonist of CR3,
Leukadherin-1, has been identified recently [15]. Current data
suggest that this drug mimics the effect of natural ligand in
inhibiting monocyte TLR-7/8-induced tumour necrosis factor
(TNF) secretion in a myeloid differentiation primary response
gene 88 (MyD88)-dependent manner [16]. In-vivo data sug-
gest that this drug has potent anti-inflammatory effects in a
range of animal models, including an autoimmune nephritis
model, without obvious short-term side effects [17,18].
Leukadherin-1 therefore appears to have therapeutic potential,
and drug mechanisms with genetic support are estimated to
succeed twice as often as those without it [19].
The NK cell is the only human cell type which constitu-
tively expresses CR3 for which there are no published data
on CR3 function. Therefore, the primary aim of our study
was to use Leukadherin-1 to explore how CR3 activation
modifies NK cell cytokine release in response to innate
immune stimuli, in a way that might be relevant to SLE
disease mechanisms. A secondary aim was to broaden the
existing published data on the influence of Leukadherin-1
on monocyte signalling, which is important to understand
in detail as part of preclinical evaluation of this potential
therapeutic. To support the possibility of using
Leukadherin-1 to ‘overcome’ the genetic defect in CR3
function due to the R77H mutation we tested ex-vivo cells
from donors homozygous for the wild-type or under-
functioning variant. Finally, using these genotyped cells we
evaluated CR3 expression across a broad range of leucocyte
subsets, thus refuting published data which suggests that
genotype influences expression.
Methods
Study design
This experimental laboratory study used ex-vivo leucocytes
from healthy donors sourced from the Cambridge Biore-
source and selected on the basis of the R77H CD11b vari-
ant, known from existing genotyping of the encoding
rs1143679 ITGAM polymorphism. It was approved by the
South East London Research Ethics committee and volun-
teers gave written informed consent. None of the volun-
teers had SLE or other systemic autoimmune disease and
none were taking steroids or immune-suppressing medica-
tion. When samples were obtained from a variant 77H
homozygous donor these were paired with a wild-type R77
homozygous donor and processed simultaneously, with
efforts made to match pairs for age [mean6 standard devi-
ation (s.d.) R77 donors 553 (134), 77H donors 482
(142)]. Laboratory investigators were blind to genotype,
with genetic information released from the Cambridge Bio-
resource at analysis. All presented data are from R77 sam-
ples except where specified.
Reagents
Fluorochrome-conjugated antibodies were from eBioscien-
ces (Hatfield, UK), anti-CD210 (IL-10R) and control from
Biolegend (London, UK) [LEAF purified (low endotoxin,
azide-free)] and rabbit anti-streptavidin antibodies from
Abcam (Cambridge, UK). iC3b, Syk inhibitor IV and
Leukadherin-1 were from Calbiochem (Beeston, UK). Salt
solutions and media were from Lifetech (Paisley, UK)
except lymphocyte growth medium from Clonetics
(Wokingham, UK). Polystyrene microspheres were from
Spherotech (Sheffield, UK), IL-12 and IL-15 from Pepro-
tech (London, UK), IL-18 from R&D Systems (Abingdon,
UK) and TLR agonists from Invivogen (San Diego, Califor-
nia, USA). Cytokines were quantified by cytometric bead
array from BD Biosciences (San Jose, California, USA).
Phosflow reagents were from BD Biosciences.
Cell isolation
We used fresh blood with a maximum 4 h between bleed
and cell purification. Peripheral blood mononuclear cells
(PBMCs) were isolated by density gradient centrifugation
and monocytes and NK cells subpurified by negative selec-
tion (Miltenyi Pan-monocyte and NK cell isolation kits;
Miltenyi Biotech, Bergisch Gladbach, Germany) and diluted
to 75 3 105/ml in serum-free medium [macrophage
serum-free medium (monocytes) or lymphocyte growth
medium (NK cells)]. The cell purity of each sample was
assessed by flow cytometry: monocytes were characterized
by their forward- and side-scatter, positive expression of
CD14 and negative expression of CD3, CD19 and CD56
and NK cells characterized by their forward- and side-
scatter, negative expression of CD3, CD19 and CD14 and
positive expression of CD56. Samples with< 95% final
purity or> 1% contamination by any single cell population
were excluded from further analysis. Viability was assessed
by trypan blue exclusion. Final isolates were 96% pure, 90%
viable (NK cells) and 98% pure, 89% viable (monocytes).
CD11b expression by flow cytometry
We used a multi-colour flow-cytometry panel (CD11b (or
isotype control), CD3, CD14, CD16 and CD56) plus for-
ward- and side-scatter to evaluate the expression of CD11b
on freshly isolated peripheral blood mononuclear cells
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following density gradient centrifugation. After exclusion
of doublets, monocytes were identified by their characteris-
tic forward- and side-scatter and lack of CD3 and CD56
expression, and then subdivided on the bases of CD14 and
CD16 expression. After exclusion of doublets, NK cells
were identified by their forward- and side-scatter (ensuring
that the gate was set wide enough to capture the larger NK
cells in the lymphocyte population), lack of CD3 and CD14
expression and positive expression of CD56.
Cell stimulation
Supernatant cytokines were quantified after stimulation
and culture for 18 h (monocytes) or 24 h (NK cells). Except
for bead-based stimulation, all experiments were con-
ducted using 100 ml cells in a 96-well plate format. NK cell
stimuli (where used) were added as follows: (1) Syk inhibi-
tor (1 lM), (2) Leukadherin-1 or dimethylsulphoxide
(DMSO) (vector control) (75 lM). Shown to induce
82% of maximum response with negligible off-target
effect [17]), (3) anti-CD210 or isotype control (5 mg/ml),
(4) 30-45 min after Leukadherin-1 NK cells were stimu-
lated with combinations of IL-12 (10 ng/ml), IL-15 (30 ng/
ml) or IL-18 (10 ng/ml): either IL-121 IL-15 or IL-
121 IL-18. Monocytes were stimulated using pam3csk4
(TLR-2 agonist, 300 ng/ml) or R848 (TLR-7/8 agonist, 2
mg/ml). Supernatants were stored at 280C for< 1 month
before quantification. To exclude non-specific Leukad-
herin-1-mediated cytotoxicity we assessed cell viability at
24 h using the CellTitre-Glo reagent (Promega, Southamp-
ton, UK). No significant loss of viability in comparison
with the DMSO control was seen, concurring with pub-
lished data in other cell types [17].
To stimulate cells through clustered Fc-receptor engage-
ment, 60–80 mm streptavidin-coated polystyrene micro-
spheres were incubated with 1 : 1000 polyclonal rabbit
anti-streptavidin immunoglobulin (Ig)G, followed by
repeated washing. NK cells were treated initially with
Leukadherin-1 (or DMSO control) and incubated with
end-over-end mixing for 30 min. Coated microspheres (1 :
8 cell : sphere ratio) were added with mixing for a further
1 h before static culture for 23 h.
Cell signalling
To measure p38, extracellular-regulated kinase (ERK), Syk
and signal transducer and activator of transcription (STAT)
phosphorylation, 2 3 105 NK cells in 200 ll medium were
stimulated as above. Non-activated samples were included
for fold-change calculation. Cells were incubated at 378C
and fixed with 4% paraformaldehyde at specified time-
points. Fixed cells were surface-stained with Pacific Blue-
conjugated anti-CD56 for 45 min, permeabilized with
PermBuffer III (BD Biosciences) on ice for 30 min, then
stained with Alexa647-conjugated phospho-specific anti-
phosphorylated STAT (pSTAT)23 (pY705), anti-pSTAT-4
(pY693), anti-pSTAT-5 (pY694), anti-p-p38 (pT180/Y182)
or anti-ERK1/2 (pT202/pY204) (BD Biosciences) for 1 h.
Samples were run on a BDCanto II Flow cytometer and
analysed with FlowJo software version 764 (TreeStar Inc.,
Ashland, OR, USA).
Statistical analysis
Normally distributed data sets were compared by two-
tailed Student’s t-test (a paired test for within-individual
comparisons and unpaired for between-individual compar-
isons). Skewed data were compared by the Wilcoxon
matched-pairs test, as specified in Results.
Results
Leukadherin-1 modulates NK cell cytokine secretion
NK cells release a well-documented repertoire of cytokines,
including interferon-g (IFN-g), TNF, macrophage inflam-
matory protein-1b [MIP-1b (CCL4)] and interleukin-8 [IL-
8 (CXCL8)], following activation by synergistic combina-
tions of monokines [20]. We observed a significant, large-
magnitude reduction in IFN-g, TNF and MIP-1b secretion
by monokine-stimulated (IL-121 IL-15, Fig. 1a; IL-121 IL-
18, Fig. 1b) NK cells that had been pretreated with
Leukadherin-1 (P < 0001 for all; Fig. 1). No effect on IL-8
secretion was observed following either monokine stimula-
tions (P 05; Fig. 1), which demonstrates that
Leukadherin-1 does not globally suppress NK cell cytokine
secretion. Unstimulated NK cells secreted only low levels of
cytokine, with neither Leukadherin-1 nor its DMSO vector,
modifying this basal secretion significantly (Fig. 1). IL-
121 IL-15 stimulated cells secreted low levels of IL-10 with
no significant change seen with Leukadherin-1 (Fig. 2). IL-
121 IL-18-stimulated cells secreted barely detectable levels
of IL-10, but a small but significant increase was seen with
Leukadherin-1 (P < 00001; Fig. 2). Fc-receptor engagement
by clustered rabbit polyclonal IgG was sufficient to induce
low-level cytokine secretion without additional stimuli.
Leukadherin-1 did not modulate the secretion of IFN-g,
TNF, MIP-1b or IL-8 under these conditions (Supporting
information, Fig. S1), but did induce the secretion of small
but significant amounts of IL-10 (P < 00001; Fig. 2).
The SLE-associated CD11b-R77H variant does not
influence NK cell response to Leukadherin-1
The SLE-associated CD11b-R77H variant impairs CR3 func-
tion significantly in response to natural ligands [11–14]. We
compared the Leukadherin-1-mediated reduction in inflam-
matory cytokine between homozygous WT (R77) and
homozygous variant (77H) genotype groups (Fig. 3). We
analysed the absolute change and the percentage change in
cytokine secretion, using both unpaired t-test to compare
genotype groups and a paired t-test for samples run in
CR3 agonist suppresses inflammatory signaling
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paired assays. Cytokine differences were not significant
between genotype groups in any analysis (P> 009 for all).
Leukadherin-1 does not modulate Syk activation in
NK cells
Monocyte studies implicate multiple mechanisms for CR3-
mediated modulation of inflammatory cytokine release,
including Syk-dependent inhibition and autocrine feed-
back by IL-10 [4,5]. We examined Syk-signalling in NK
cells and found that, in contrast to natural ligand-engaged
monocytes, Syk inhibition augmented rather than abro-
gated the inhibition of NK cell cytokine secretion seen with
Leukadherin-1 (Supporting information, Table S1). We
also evaluated Syk activation by phosphorylation (pSyk)
using Phosflow. After 30 min incubation with
Leukadherin-1 (or DMSO control) we observed no differ-
ence in NK pSyk fluorescence intensity (paired t-test; total
NK cells (n5 12) P5 053; CD56hi NK cells (n5 11),
P5 060, Supporting information, Fig. S2).
To evaluate whether IL-10 autocrine feedback explained
the effect of Leukadherin-1 in NK cells we co-incubated
with anti-CD210 (IL-10 receptor) blocking antibodies. We
Fig. 1. Leukadherin-1 (LA1) modulates natural killer (NK) cell inflammatory cytokine secretion. Using cytometric bead array we showed that
LA1 pretreatment reduced the interferon (IFN)-g, tumour necrosis factor (TNF) and macrophage inflammatory protein (MIP)-1b release in
primary NK cell cultures stimulated with (a) interleukin (IL)-121IL-15 (n5 20) and (b) IL-121IL-18 (n5 28). Dimethylsulphoxide (DMSO)
provides the carrier control for LA1. Data presented are mean6 standard error of the supernatant cytokine concentration pg/ml at 24 h.
Statistical testing by two-tailed paired t-test.
Fig. 2. The effect of Leukadherin-1 (LA1) on the secretion of
interleukin (IL)210 by natural killer (NK) cells. Using cytometric
bead array we showed that LA1 pretreatment does not affect the
IL-10 production by cultured primary NK cells stimulated with
IL-121 IL-15 (n5 20). LA1 pretreatment significantly increases
the IL-10 production by primary NK cell cultures stimulated by
IL-121 IL-18 (n5 19) and immunoglobulin (Ig)G-coated beads
(n5 12). Dimethylsulphoxide (DMSO) provides the carrier control
for Leukadherin. Data presented are median6 interquartile range of
the supernatant cytokine concentration (pg/ml) at 24 h. Statistical
testing by Wilcoxon’s matched pairs test.
A. L. Roberts et al.
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observed no significant difference in cultured primary NK
cell release of IFN-g, TNF, IL-8, and MIP-1b in the presence
of anti-CD210 antibody (Supporting information, Fig. S3).
The effects of Leukadherin-1 are STAT-4-independent
To ascertain whether the Leukadherin-1 effects were
specific to IL-12 signalling in both stimulation conditions
(IL-121 IL-15 and IL-121 IL-18), we used PhosFlow to
measure its effects on STAT-4 phosphorylation across
multiple time-points ranging from 5 min to 4 h. Using cell
surface staining of CD56 also enabled the simultaneous
identification and analysis of the CD56hi subset, which are
the most efficient cytokine-producing NK cell subset. As
expected, we observed fold-change increases in pSTAT-4
following both IL-121 IL-15 and IL-121 IL-18 stimula-
tion in both cell populations (Fig. 4a). No difference in
median fold-change of pSTAT-4 was observed following
Leukadherin-1 pretreatment in either IL-121 IL-15 or IL-
121 IL-18-stimulated cells (P> 01 all; Fig. 4b).
CR3 modulates IL-15-mediated STAT-5
phosphorylation
We next measured the effects of Leukadherin-1 on the
phosphorylation of intercellular signalling molecules
known to be important in IL-15 and IL-18 signal transduc-
tion – mitogen-activated protein kinase (MAPK) p38,
ERK, STAT-3 and STAT-5 [21,22] – in stimulated NK cells
across multiple time-points. We observed a reduction in
pSTAT-5 at all time-points (Fig. 5), both in the magnitude
of pSTAT-5 induction (fold-change from time zero)
(Fig. 5a,d) and in the proportion of pSTAT-5-positive cells
(Fig. 5b), in IL-121 IL-15-stimulated cells pretreated with
Fig. 3. The systemic lupus erythematosus (SLE)-associated CD11b-R77H polymorphism does not affect the response of natural killer (NK) cells
to Leukadherin-1 (LA1). LA1 pretreated NK cells were compared for CD11b-R77H genotype groups [wild-type (WT) versus the rarer 77H
variant]. Data presented as mean6 standard error reduction in cytokine secretion by NK cells consequent upon LA1 pretreatment. None of the
observed differences are statistically significant (P> 009 for all).
Fig. 4. Leukadherin-1 (LA1) does not modulate signal transducer and activator of transcription (STAT)-4 phosphorylation. Using Phosflow intracellular
flow cytometry assay we showed (a) the fold-change increases in phosphorylated (p)STAT-4 in total (left panel) and CD56hi (right panel) natural killer
(NK) cells, following IL-121IL-15 (top panel) and IL-121IL-18 (bottom panel) stimulation, is not modulated by LA1 pretreatment (data presented as
log2 median fold-change; 3 n 9 per time-point). (b) No statistical difference was observed at early (10 min) or late (120 min) time-points (P> 01
for all). Testing by Wilcoxon’s matched-pairs test. Dimethylsulphoxide (DMSO) provides the carrier control for LA1 in all panels.
CR3 agonist suppresses inflammatory signaling
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Leukadherin-1. This difference was seen in both the total
NK cells and the CD56hi subpopulation. The effect is appa-
rent from the earliest time-point (5 min) and most signifi-
cant at 10 min (Fig. 5c; total NK P5 002; CD56hi
P5 0004), suggesting a mechanism of inhibited STAT-5
phosphorylation rather than initiation of a dephosphoryl-
ation mechanism. No difference was observed in the
median fold-change of pSTAT-5 in Leukadherin-1 pre-
treated IL-121 IL-18 cells (Supporting information, Fig.
S4). Additionally, Leukadherin-1 did not affect the median
fold-change of phosphorylation in MAPK p38, ERK, or
STAT-3 under either IL-121 IL-15 or IL-121 IL-18-
stimulated cells (Supporting information, Fig. S4).
Leukadherin-1 modulates TLR-2 and TLR-7/8-
induced monocyte cytokine secretion
It has been reported previously that Leukadherin-1 modu-
lates the secretion of TNF secretion by monocytes follow-
ing TLR-7/8-stimulation [16]. We tested the hypothesis
that Leukadherin-1 modulates an entire cytokine repertoire
following TLR-7/8 stimulation and also modulates cytokine
production in response to stimulation of TLR-2. We
observed a significant down-regulation of the secretion of
monocyte inflammatory cytokines interleukin-1b (IL-1b;
P < 0001) and interleukin-6 (IL-6; P5 0008), in addition
to TNF (P5 0009), following TLR-7/8 stimulation (Fig.
6a). We saw similar down-regulation of TNF (P5 0004),
IL-1b (P5 0002), and IL-6 (P5 0003) secretion in TLR-
2-stimulated monocytes (Fig. 6b).
IL-10 was secreted at low levels by monocytes following
either TLR-2 (Fig. 6c) or TLR-7/8 (Fig. 6d) stimulation,
but was modified only weakly by Leukadherin-1. Undetect-
able (TLR-2 stimulation) or barely detectable (TLR-7/8
stimulation) levels of IL-12 were seen following TLR activa-
tion alone, with a very small but significant increase seen
with the addition of Leukadherin-1 (Fig. 6c, P5 0002;
Fig. 6d, P5 0008).
Fig. 5. The effect of Leukadherin-1 (LA1) on natural killer (NK) cell signal transducer and activator of transcription (STAT)-5 phosphorylation.
Using Phosflow intracellular flow cytometry assay we showed that LA1 pretreatment (a) reduced interleukin (IL)-15-mediated phosphorylated
(p)STAT-5 fold-change in both total (left panel) and CD56hi (right panel) NK cells across multiple time-points (data presented as log2 median
fold-change; 3 n 9 per time-point) and (b) reduced the percentage of pSTAT-5-positive cells (x-axis) following IL-121 IL-15 stimulation
(blue). Basal levels of pSTAT-5 are shown in red where no difference was observed. Representative data shown (t5 10min). (c) The median fold
induction of pSTAT-5 at 10 min was significantly lower in LA1-treated cells in both total NK cells (left panel) and CD56hi cells (right panel)
(n5 9), and approached significance for both cell populations at 2 h (n5 6). Statistical testing by Wilcoxon’s matched-pairs test. (d) pSTAT-5
fold-change was observed to be consistently lower following LA1 pretreatment (red curve), during short- and long-term IL-121IL-15 stimulation
in total NK cells (left panel) and the CD56hi subset (right panel). Data presented as median fold-change of pSTAT5 (3 n 9 per time-point).
Dimethylsulphoxide (DMSO) provides the carrier control for LA1 in all panels.
A. L. Roberts et al.
366 VC 2016 The Authors. Clinical and Experimental Immunology published by John Wiley & Sons Ltd on behalf of British
Society for Immunology, Clinical and Experimental Immunology, 185: 361–371
The CR3 R77H variant does not affect cell surface
expression of CR3 on monocytes or NK cells
A recent study suggested that the minor allele of the SLE-
associated rs1143679 (R77H) polymorphism is associated
with reduced cell surface expression of CD11b on ex-vivo
monocytes [8]. We used a multi-colour flow-cytometry
panel as outlined in the Methods section to evaluate the
expression of CD11b on monocyte and NK cell subsets
between homozygous WT (R77) (n5 22) and homozygous
variant (77H) (n5 17) genotype groups. In the monocyte
population we compared four subgroups: total monocytes,
CD14hi/CD16– cells (classical monocytes), CD14– (non-
classical monocytes) and also all CD161 monocytes. As we
observed previously in an earlier study, there was no signif-
icant difference (P5 01) in the cell surface expression of
Fig. 6. Leukadherin-1 (LA1) modulates monocyte inflammatory cytokine secretion. Using cytometric bead array we showed that LA1
pretreatment reduced the interkeukin (IL)-1b, IL-6 and tumour necrosis factor (TNF) release in monocyte cultures stimulated with (a) Toll-like
receptor (TLR)-7/8 agonist R848 (n5 18) and (b) TLR-2 agonist Pam3csk4 (n5 11). We also showed that LA1 pretreatment (c) increased the
IL-12 release but did not affect the IL-10 release by monocyte cultures stimulated with TLR-7/8 agonist R848 (n5 18) and (d) increased the IL-
10 and IL-12 release by monocyte cultures stimulated with TLR-2 agonist Pam3csk4 (n5 11). Data presented in (a) and (b) are mean6 standard
error of the supernatant concentration in pg/ml at 18 h, and statistical testing by paired t-test. Data presented in (c) and (d) are median6
interquartile range of the supernatant cytokine concentration in pg/ml at 18 h, and statistical testing by Wilcoxon’s matched-pairs test.
Dimethylsulphoxide (DMSO) provides the carrier control for LA1.
Fig. 7. Systemic lupus erythematosus (SLE)-associated R77H does not affect cell surface expression of CD11b on natural killer (NK) cells and
monocytes. There was no difference in CD11b expression (anti-CD11b fluorescence – isotype control) on primary monocytes and NK cells
between CD11b-R77H homozygote genotype groups [wild-type (WT) versus 77H]. CD14 and CD16, and CD56 cell surface markers were used to
identify monocyte and NK cell subsets, respectively. No genotypic difference was observed in any cell subset (P> 009 for all). Mean fluorescence
intensity (MFI) for each donor is displayed. Statistical testing by unpaired t-test.
CR3 agonist suppresses inflammatory signaling
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CD11b on any monocyte subset between the two homozy-
gous genotype groups (Fig. 7) [12]. In the NK cell popula-
tion we also compared three subgroups: total NK cells, the
small subset characterized by CD56hi expression and the
larger subset with regular CD56 expression only. Similarly,
there was no significant difference in CD11b expression
between the two genotype groups (P> 043 for all) (Fig.
7).
Discussion
We have demonstrated that Leukadherin-1 exerts a marked
functional effect on the release of proinflammatory cyto-
kines by monokine-primed (IL-121 IL-15/IL-18) NK cells.
Similar to previous reports in monocytes, this effect was
broadly anti-inflammatory. Whether this pathway contrib-
utes to the pathogenesis of SLE, and whether there is
potential to manipulate this therapeutically using
Leukadherin-1, is an intriguing question.
Several lines of evidence implicate NK cells in the patho-
genesis of SLE. For example, circulating NK cell numbers
are reduced (probably migrated to lymphoid organs), but
produce higher levels of interferon-g [23]. NK cells up-
regulate the production of type 1 interferon (characteristi-
cally high in SLE) by co-cultured plasmacytoid dendritic
cells following stimulation by RNA-containing lupus
immune complexes [24]. There is evidence from the
B6.Sle1 murine SLE model of an NK cell-dependent, T cell-
independent pathway of autoantibody production, with
lower anti-nuclear antibody levels in NK-depleted animals
[25]. Finally, there is a precedent for penetrant SLE genetic
susceptibility effects (Fc-receptor locus copy-number varia-
tion) leading to changes in NK cell phenotype [26]. We
also know that monocytes are activated in SLE and produce
monocyte-derived cytokines (monokines). Both IL-15 and
IL-18 are elevated in the serum of patients with lupus,
along with an increase in leucocyte membrane-bound IL-
15 [27,28]. These monokines can trigger the early release of
TNF and IFN-g from NK cells, thus perpetuating a proin-
flammatory milieu independent of, and most probably
before, activation of the adaptive immune system.
Our results demonstrate that CR3 is a negative regulator
of this inflammatory loop and that Leukadherin-1 is capa-
ble of marked NK cell cytokine down-regulation. Further-
more Leukadherin-1 is equally capable of down-regulating
signalling even in cells that are homozygous for the geneti-
cally encoded under-functioning variant of CR3, presum-
ably because the mechanism of CR3 signal transduction is
different following engagement with this small molecule
compound compared with natural ligand. We did not dem-
onstrate any significant effect of Leukadherin-1 in modu-
lating cytokine production following engagement of CD16
on NK cells. Whether this would also apply to other CD16-
mediated functions, such as antibody-dependent cellular
cytotoxicity (ADCC), would require further investigation.
In addition to documenting ex-vivo effects of
Leukadherin-1 we have, in part, explained the mechanism
in NK cells by demonstrating an inhibition of IL-15-
induced phosphorylation of the transcription factor STAT-
5. Our data suggest that Leukadherin-1 interferes with
events that take place upstream of, or during, STAT-5 phos-
phorylation – such as Janus kinase (JAK) phosphorylation
or JAK/STAT association – rather than through a mecha-
nism of STAT dephosphorylation. Activation of JAK-1 and
JAK-3 associated with the IL-2Rb and gc-chains, respec-
tively, has been shown to be crucial for STAT-5 tyrosine
phosphorylation in response to IL-15 [22,29]. A CR3-
mediated effect on JAKs has been shown recently in human
monocytes/macrophages, in which CR3 activation with
anti-CD18 or anti-CD11b antibodies blocks the phospho-
rylation of IL-13 receptor-associated JAK-2 and tyrosine
kinase-2 (TYK-2) kinases, which further inhibits the down-
stream tyrosine and serine phosphorylation of STAT-1,
STAT-3 and STAT-6 [30]. Further work is needed to deter-
mine the upstream mechanism through which the
Leukadherin-1-mediated inhibition of STAT-5 phosphoryl-
ation occurs in NK cells.
We have also shown that the modulation of NK cells by
Leukadherin-1 is STAT-4-independent. STAT4 polymor-
phisms are robustly associated with SLE [31], and our data
suggest that the effects of Leukadherin-1 will not be con-
founded by SLE-associated STAT4 polymorphisms. We have
also discounted Syk-activation and IL-10 autocrine feedback,
both of which are important mechanisms in monocytes fol-
lowing engagement by natural ligand. Clearly, pSTAT-5 inhi-
bition is not the only Leukadherin-1 influenced pathway in
NK cells, because IL-121 IL-18 stimulation was not associ-
ated in any notable STAT-5 phosphorylation: Leukadherin-1
must operate differently under these conditions and this will
require further experimental evaluation.
Having conducted a novel evaluation of NK cells, we then
aimed to replicate and significantly extend existing data on
the effect of Leukadherin-1 in monocytes. We demonstrated a
broad inhibition of proinflammatory cytokines (TNF, IL-1b
and IL-6) following activation of both TLR-7/8 and TLR-2.
TLR activation is recognized increasingly as an element of
SLE pathogenesis. SLE is characterized by the production of
high-affinity antibodies that target nuclear protein/nucleic
acid antigens (Ro, La, RNP and Sm) and anti-dsDNA [32].
These antigens function as immunological adjuvants by acti-
vating nucleic acid-sensing TLR-7/8 and -9 [33,34]. The acti-
vation of monocyte TLR-7/8 triggers the production of
inflammatory cytokines (IL-1b, IL-6, TNF) and cytokines
which augment the adaptive immune response (IL-12, IL-18)
[34,35]. The activation of TLR-2 by components of late-
apoptotic and secondary necrotic cells may be another inflam-
matory mechanism in SLE, where defective apoptotic cell
clearance is well described [36]. In particular, high mobility
group box 1 (HMGB1) containing nucleosomes from apopto-
tic cells generate a TLR-2-dependent inflammatory response
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and, as a component of dsDNA-containing immune com-
plexes, induce TLR-2-dependent anti-dsDNA antibody pro-
duction [37,38].
In addition, we have demonstrated that the SLE-
associated R77H variant does not affect the cell surface
expression of CD11b on ex-vivo monocytes and NK cells. A
recent study by Maiti et al., in contradiction to other pub-
lished reports, suggested a genotypic difference in CD11b
expression on CD14 positively selected monocytes [8]. We
believe our data from freshly isolated peripheral blood
mononuclear cells following density gradient centrifugation
to be robust, with minimal confounding factors from posi-
tive selection of cell populations. Our comprehensive
expression data demonstrate stark variation in CD11b across
the three monocyte subsets, as shown previously for other
cell surface receptors, but no genotype effect [39].
Genetic and functional studies implicate under-
functioning CR3 as a risk factor for SLE, suggesting intui-
tively that augmenting CR3 function may be an effective
therapeutic approach [9–14]. Our data suggest that there is
a potential to achieve this using a small-molecule com-
pound which, ex-vivo, exerts broadly anti-inflammatory
effects on two innate immune cell types. In other auto-
immune diseases innate immune activation drives inflam-
mation, even if it is not an initial disease trigger. For
example, intra-articular monocyte/macrophage TLR acti-
vation may perpetuate joint inflammation in rheumatoid
arthritis [40]. Therapeutic inhibition of TLRs and their
downstream signalling has been proposed for both SLE
and rheumatoid arthritis: indirect modulation by
Leukadherin-1 may be a realistic alternative strategy [41].
There are caveats. For example, the small induction of IL-12
by Leukadherin-1-treated monocytes runs contrary to the
anti-inflammatory trend: whether this low concentration is of
any functional significance needs to be determined. Further
evaluation of Leukadherin-1 in other cell types will be impor-
tant because we have already seen a proposed role for CR3
immune signalling not only in monocytes, but in B cells and
dendritic cells as well [6,7]. Despite the caveats, initial reports
from animal studies suggest efficacy in a range of inflamma-
tory models, including vascular injury, chemical peritonitis
and immune complex nephritis with low 60-day toxicity
[17,18]. Our data extend this to demonstrate encouraging
anti-inflammatory effects in a broad range of human ex-vivo
cell assays. There is considerable scientific rationale to support
the hypothesis that CR3 activation is of therapeutic potential
in a range of inflammatory disease situations. We would sup-
port continued evaluation in relevant animal models and the
accrual of longer-term safety data, with a view to future trials
in human disease.
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Supporting information
Additional Supporting information may be found in the
online version of this article at the publisher’s web-site:
Fig. S1. The effect of Leukadherin-1 (LA1) on inflammatory
cytokine secretion by Fc-receptor engaged natural killer
(NK) cells. Cells were pretreated with LA1 and stimulated
using immunoglobulin (Ig)G-coated polystyrene particles
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(n5 12). Dimethylsulphoxide (DMSO) provides the vector
control for LA1. Data presented are mean6 standard error
of the supernatant cytokine concentration at 24 h. Statistical
testing by two-tailed paired t-test.
Fig. S2. The effect of Leukadherin-1 (LA1) on Syk phos-
phorylation. Cells were incubated with either LA1 or
dimethylsulphoxide (DMSO) for 30 min (n5 12). DMSO
provides the vector control for LA1. Cells were permeabal-
ized and stained with Alexa647 anti-pSyk. Data presented
are mean6 standard error of the median fluorescence of
pSyk. Statistical testing by two-tailed paired t-test.
Fig. S3. The effect of interleukin (IL)-10 receptor-
blocking antibodies on IL-121IL-15- and IL-121IL-18-
stimulated natural killer (NK) cell cytokine secretion. NK
cells were incubated with anti-CD210 antibody or isotype
control together with IL-121IL-15 (top panel) or IL-12–
IL-18 (bottom panel). Data presented are mean6
standard error of the supernatant cytokine concentration
at 24 h. Statistical testing by two-tailed paired t-test.
Fig. S4. The effect of Leukadherin-1 (LA1) on in p38,
extracellular-regulated kinase (ERK), signal transducer
and activator of transcription (STAT)-3 phosphorylation.
(a) Heat map (log2 median fold-change) of effects of LA1
pretreatment on phosphorylated STAT (pSTAT)-43, p-
p38, pERK and pSTAT-5 following natural killer (NK) cell
stimulation with interleukin (IL)-121IL-18 (top panel)
and IL-121 IL-15 (lower panel) in total NK cells (left
panel) and CD56hi (right panel) across multiple time
points. Three to nine samples per time-point.
Table S1. The effect of Syk blockade on cytokine secre-
tion by stimulated, Leukadherin-1 treated natural killer
(NK) cells
CR3 agonist suppresses inflammatory signaling
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